4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties |
| |
Authors: | Butora Gabor Morriello Gregori J Kothandaraman Shankaran Guiadeen Deodialsingh Pasternak Alexander Parsons William H MacCoss Malcolm Vicario Pasquale P Cascieri Margaret A Yang Lihu |
| |
Affiliation: | Merck Research Laboratories, Rahway, NJ 07065, USA. gabor_butora@merck.com |
| |
Abstract: | A systematic examination of the central aromatic portion of the lead (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-(4-fluorophenyl)-4-(1'H-spiro[indene-1,4'-piperidin]-1'-yl)butanamide (9) led to the discovery of a novel class of CCR2 receptor antagonists, which carry small alicyclic groups such as cyclopropyl, cylobutyl, or cyclopropylmethyl attached at C2 of the carbon backbone. The most potent compound discovered, namely (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-cyclopropyl-4-[(1R,3'R)-3'-methyl-1'H-spiro[indene-1,4'-piperidin]-1'-yl]butanamide (29), showed very high binding affinity (IC50 = 4 nM, human monocyte) and excellent selectivity toward other related chemokine receptors. The excellent pharmacokinetic profile of this new lead compound allows for extensive in vivo evaluation. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|